Skip to content

LivaNova LIVN Stock-Based Comp

Stock-Based Comp at other companies

Haemonetics logo
HaemoneticsHAE
Medtronic logo
MedtronicMDT
ResMed logo
ResMedRMD
Merit Medical Systems logo
Merit Medical SystemsMMSI
Globus Medical logo
Globus MedicalGMED
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's stock-based comp?
LivaNova (LIVN) reported stock-based comp of $8.27M in Q1 2026.
How has LivaNova's stock-based comp changed year-over-year?
LivaNova's stock-based comp increased by 6.3% year-over-year, from $7.78M to $8.27M.
What is the long-term trend for LivaNova's stock-based comp?
Over 4 years (2021 to 2025), LivaNova's stock-based comp has grown at a -2.7% compound annual growth rate (CAGR), from $40.56M to $36.29M.